Search Immortality Topics:

Page 11234..1020..»

Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Se | JAA – Dove Medical Press

Posted: December 9, 2019 at 6:46 pm

J Mark FitzGerald,1 Eugene R Bleecker,2 Arnaud Bourdin,3 William W Busse,4 Gary T Ferguson,5 Laura Brooks,6 Peter Barker,6 Ubaldo J Martin6

1Centre for Heart and Lung Health, The Lung Centre Vancouver General Hospital, UBC Institute for Heart and Lung Health, Vancouver, BC, Canada; 2Divisions of Pharmacogenomics and Genetics, Genomics and Precision Medicine, University of Arizona College of Medicine, Tucson, AZ, United States; 3Department of Respiratory Diseases, Hpital Arnaud De Villeneuve, Montpellier, France; 4Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States; 5Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, United States; 6AstraZeneca, Gaithersburg, MD, United States

Correspondence: J Mark FitzGeraldThe Lung Centre, Vancouver General Hospital, Gordon and Leslie Diamond Health Care Centre, 2775 Laurel Street, Vancouver BC V5Z 1M9, CanadaTel +1604-875-4122Email

Background: Benralizumab is an interleukin-5 receptor alphadirected cytolytic monoclonal antibody. Treatment with benralizumab significantly reduces exacerbations and improves lung function after 1 year for patients with severe, uncontrolled eosinophilic asthma.Objective: We explored whether benralizumab efficacy was sustained after an additional year of treatment while maintaining an acceptable safety profile.Methods: Data from the pivotal 48-week SIROCCO and 56-week CALIMA studies were integrated with data from the predefined 56-week adult phase of the BORA extension study to provide a 2-year integrated efficacy and safety analysis of benralizumab. BORA enrolled patients who had completed SIROCCO or CALIMA. Patients receiving benralizumab 30 mg subcutaneously, either every 4 weeks (Q4W) or every 8 weeks (Q8W; first three doses Q4W), were assessed. Efficacy was evaluated based on baseline blood eosinophil counts from the pivotal studies (300 and Results: Mean treatment exposures were 24.3 (Q4W, n=518) and 24.6 (Q8W, n=512) months. Exacerbation frequency reductions observed in SIROCCO/CALIMA were maintained; 50% of the patients had no exacerbations during the 2-year study period (crude exacerbation rate, Q8W: 0.56 exacerbations/year for patients with blood eosinophil counts 300 cells/L). Lung function improvements with benralizumab were maintained for 2 years, as represented by increases in mean prebronchodilator forced expiratory volume in 1 second from baseline of 0.343 L and 0.364 L with 1 and 2 years of benralizumab Q8W treatment, respectively, for patients with blood eosinophil counts 300 cells/L. Health-related quality of life improvements with benralizumab observed in the pivotal studies were also sustained. Adverse events and serious adverse event rates were similar between the BORA extension and SIROCCO/CALIMA periods, with no new or unexpected occurrence of adverse events.Conclusion: This benralizumab 2-year integrated analysis further supports long-term use of benralizumab for patients with severe, uncontrolled eosinophilic asthma.

Keywords: asthma, benralizumab, clinical features, eosinophilic inflammation, interleukin-5 receptor, safety

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Excerpt from:
Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Se | JAA - Dove Medical Press

Recommendation and review posted by G. Smith

Chemistry focus: The rapid development of nanotechnology – Open Access Government

Posted: December 9, 2019 at 6:44 pm

The author reveals that nanotechnology has developed at a rapid pace during the last few decades and as such, had revolutionised industries like computing, medicine and energy. The excitement does not stop there, however, as discovery in the field and implementation of novel functional nanomaterials in the future could address challenges that face us all, including solar fuel generation and battery technology advancement, sustainable energy use and climate change.

An important focus here concerns laser ablation in liquid (LAL), which the author describes as, as a flexible synthetic route to a variety of nanomaterials that overcomes this major drawback of wet-chemical synthesis. In this vein, one of the many things we discover is that LAL has the potential to become a versatile platform for environmentally sustainable nanotechnology development.

The crucial work taking place at the Department of Chemistry at Virginia Commonwealth University is giving fundamental knowledge that will help overcome a key limitation of LAL methods insufficient control over the properties of the nanomaterial products. Looking ahead, efforts in the field will make LAL a key methodology for sustainably producing novel nanomaterials that can answer grand societal challenges in energy and other fields.

Editor's Recommended Articles

Read the original post:
Chemistry focus: The rapid development of nanotechnology - Open Access Government

Recommendation and review posted by G. Smith

FG to harness benefits of nanotechnology – Daily Trust

Posted: December 9, 2019 at 6:44 pm


The Federal Government will soon produce a national nanotechnology policy to guide the operation of nanotechnology in the country, the Permanent Secretary of the Federal Ministry of Science and Technology, Mr. Bitrus Bako Nabasu has said.

When it is eventually produced, the policy will spearhead the use of nanotechnology in the country and would make products to be lighter, smaller, stronger, cleaner and precise, Mr Nabasu said.

The Permanent Secretary said this when he Inaugurated the Committee on the First Validation Exercise on the Draft National NanoTechnology Policy Document in Abuja on Friday.

He mandated the Committee to produce a National Nanotechnology policy to guide the operation of Nanotechnology in the country, assume responsibility, and come up with a draft National Nanotechnology policy document.

He said Nanotechnology is an emerging technology set to revolutionise the manufacturing technology process by making most products lighter, smaller, stronger, cleaner and very precise.

Mr. Nabasu said that application and utilization of this technology is being made in various fields such as agriculture, health, medicine, and chemical industries to enhance the quality of lives of citizens.


Share your story with us: 08189301900 (Whatsapp and SMS only) Email:

Complain about a story or Report an error and/or correction: +2348189301900

DISCLAIMER: Comments on this thread are that of the maker and they do not necessarily reflect the organizations stand or views on issues.

Follow this link:
FG to harness benefits of nanotechnology - Daily Trust

Recommendation and review posted by G. Smith

After 20 years of hiring, I refuse to look at resumes that have this common yet outdated section – CNBC

Posted: December 9, 2019 at 6:44 pm

Over the past 20 years, I've reviewed thousands of resumes, and despite the vast amount of information available on how to write one, only a shockingly small amount of people do it well.

The most impressive resumes concisely and compellingly illustrate one major message: "This is how I made things better for the companies I worked for." But the one section that gets in the way of this objective is ... well, the "objective" those few words up at the very top, meant to capture the entirety of a candidate's career ambitions. Instead, they don't really say anything at all.

It's highly outdated and unnecessary. And yet, I still get so many resumes that have one. While it might sound harsh, 90% of the time, I refuse to read through resumes that include an objective.

Virtually every objective I've read has either been too broad or too short, never just right. To say that you're "seeking a challenging team leadership position" might be true, but it still reveals nothing about what you can do for a prospective employer.

Here are some extreme examples from the Hall of Shame that illustrate why you need to eliminate the objective:

The first one is oddly specific and sounds more like a list of demands than genuine interest in the company. The second is just too "in your face," while the last objective sounds overly presumptuous.

To say that you're 'seeking a challenging team leadership position' might be true, but it still says nothing about what you can do for a prospective employer.

Gary Burnison

CEO, Korn Ferry

In general, an objective distracts the hiring manager from focusing on what benefits you bring to the table. It can also make you seem pigeonholed and ruin your chances of being considered for other great opportunities and open positions (because the hiring manager will assume they may be too different from your stated objective).

If you're a job seeker with only few years of experience, a "headline" is a quick way to make an impact. The headline appears below your name, address and other contact information. Here are a few great examples:

For mid-level professionals with several years of experience, valuable technical skills and expertise that directly relates to the contribution they will make to their next employer, a "summary" will suffice.

A solid summary might look something like this: "Financial executive with extensive experience building and leading teams. Areas of expertise include: Strategic planning, business process reengineering, SEC reporting and governance..."

Hiring managers hardly spend any time looking at your resume (their first glance lasts about six seconds) if it doesn't immediately deliver what they're looking for. So it's important to use what little amount of space you have wisely.

Gary Burnison is the CEO of Korn Ferry, a global consulting firm that helps companies select and hire the best talent. His latest book, a New York Times best-seller, "Lose the Resume, Land the Job," shares the kind of straight talk that no one will tell you. Follow him on LinkedIn here.

Don't miss:

Here is the original post:
After 20 years of hiring, I refuse to look at resumes that have this common yet outdated section - CNBC

Recommendation and review posted by G. Smith

Nanotechnology Market 2019 Industry Outlook, Comprehensive Insights, Growth and Forecast 2025 – BoundWatch

Posted: December 9, 2019 at 6:44 pm

The Nanotechnology research report is a valuable source of data for business strategists. It provides the Nanotechnology overview with growth analysis and historical and futuristic cost revenue demand and supply data. The research analysis provides an elaborative description of the value chain and distributor analysis.

Request Sample Copy of This Report: @

The Nanotechnology market study provides comprehensive data that enhance the understanding, scope and application of this report.

The report provides a basic overview of the industry including definitions and classifications. The Nanotechnology analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Prominent players of Nanotechnology market:

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc):

Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

This report studies the Nanotechnology status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyses the top players in global market, and splits the Nanotechnology By product type and applications/end industries.

Read Detailed Index of full Research Study at @

To comprehend 2018-2026 Nanotechnology dynamics in the world mainly, the worldwide 2018-2026 Nanotechnology is analyzed across major global regions. Nanotechnology Also provides customized specific regional and country-level reports for the following areas.

North America: United States, Canada, and Mexico.

South & Central America: Argentina, Chile, and Brazil.

Middle East & Africa: Saudi Arabia, UAE, etc

The study objectives of this report are:

To study and forecast the market size of Nanotechnology

To analyze the global key players, SWOT analysis, value and global market share for top players.

To define, describe and forecast the market by type, end-use and region.

To analyses and compare the market status and forecast among global major regions.

To analyses the global key regions market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends and factors driving or inhibiting market growth.


Check here for the [emailprotected]

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs.

View original post here:
Nanotechnology Market 2019 Industry Outlook, Comprehensive Insights, Growth and Forecast 2025 - BoundWatch

Recommendation and review posted by G. Smith

FIU researcher named Fellow of the National Academy of Inventors – PRNewswire

Posted: December 9, 2019 at 6:44 pm

MIAMI, Dec. 9, 2019 /PRNewswire/ -- Florida International University Distinguished Professor Madhavan Nair has been named a Fellow of the National Academy of Inventors (NAI).

Nair, an internationally renowned expert in nanotechnology and HIV research, is the founding chair of the Herbert Wertheim College of Medicine's Department of Immunology and Nano-Medicine. He is also associate vice president of nanomedicine, associate dean of biomedical research, and director of the Institute of NeuroImmune Pharmacology at FIU.

"This distinction is a fitting tribute to the immense contributions of Dr. Nair to the scientific fields of immunology and of nanotechnology. Importantly, Dr. Nair's legacy of discoveries and inventions will yield better outcomes for patients suffering from AIDS and other types of life-threatening diseases," said Dr. Robert Sackstein, dean of the Herbert Wertheim College of Medicine and senior vice president for Health Affairs.

The NAI Fellows Program highlights academic inventors who have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society. Election as an NAI Fellow is the highest professional distinction accorded solely to academic inventors.

Nair's current research focuses mainly on the role that drug abuse of various substances like alcohol, morphine, cocaine, and methamphetamine has on neuro-AIDS, neurological disorders caused primarily by HIV damage to the central and peripheral nervous systems. Nair is also developing therapeutic approaches to control neuro-AIDS by specific drug targeting to the brain using his own patented nanotechnology. Nair is the first FIU researcher to earn a prestigious MERIT Award from the National Institutes of Health recognizing outstanding competence and productivity in research. He holds 14 U.S patents and has published more than 250 papers as first and/or senior author.

The NAI Fellows Induction Ceremony will be held next April in Phoenix, Arizona.

Media Contact: Ileana Varela 305-348-4926 @FIUNews

SOURCE Florida International University

See original here:
FIU researcher named Fellow of the National Academy of Inventors - PRNewswire

Recommendation and review posted by G. Smith

Page 11234..1020..»